Catatonia: Clinical aspects and neurobiological correlates

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 21, Issue 4, 2009, Pages 371-380

  Daniels, Jessica ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMANTADINE; AMOXICILLIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CLARITHROMYCIN; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; HEPARIN; LORAZEPAM; MEMANTINE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; RISPERIDONE; SIBUTRAMINE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZOLPIDEM;

ANTICHOLINERGIC EFFECT; ASPIRATION PNEUMONIA; CATATONIA; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DECUBITUS; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; FLEXION CONTRACTURE; HUMAN; INFECTION; LUNG EMBOLISM; MEDICAL LITERATURE; MENTAL DISEASE; NEUROBIOLOGY; NEUROLEPTIC MALIGNANT SYNDROME; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; REHABILITATION; REVIEW; RHABDOMYOLYSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; URINE RETENTION;

EID: 73549121544     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2009.21.4.371     Document Type: Review

References (99)

1. Van der Heijden, Tuinier S, Arts NJ, et al: Catatonia: disappeared or under-diagnosed? Psychopathology 2005; 38:3-8
2. Taylor MA, Fink M: Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233-1241
3. Barnes MP, Saunders M, Walls TJ, et al: The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 1986; 49: 991-996
4. Bush G, Fink M, Petrides G, et al: Catatonia I: rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129-136
5. Rosebush PI, Hildebrand AM, Furlong BG, et al: Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357-362
6. Carroll BT, Goforth HW: Medical catatonia, in Catatonia: From Psychopathology to Neurobiology. Edited by Caroff SN, Mann SC, Francis A, et al. Washington, DC, American Psychiatric Publishing, 2004, p 123
7. Fink M, Taylor MA: Catatonia is measurable and common, in Catatonia: A Clinician's Guide to Diagnosis and Treatment. New York, Cambridge University Press, 2003, pp 129-130
8. Kruger S, Bagby RM, Hoffler J, et al: Factor analysis of the catatonia rating scale and catatonic symptom distribution across four diagnostic groups. Compr Psychiatry 2003; 44:472-482
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, pp 169-170, 382-383
10. Rosebush PI, Mazurek MF: Pharmacotherapy, in Catatonia: From Psychopathology to Neurobiology. Edited by Caroff SN, Mann SC, Francis A, et al. Washington, DC, American Psychiatric Publishing, 2004, p 145
11. Northoff G: What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behavioral and Brain Sciences 2002; 25:555-604
12. Mann SC, Caroff SN, Bleier HR: Lethal catatonia. Am J Psychiatry 1986; 123:1374-1381
13. Moskowitz AK: "Scared stiff": catatonia as an evolutionary fear-based response. Psychol Rev 2004; 111:984-1002
14. Philbrick KL, Rummans TA: Malignant catatonia. J Neuropsychiatry Clin Neurosci 1994; 6:1-13
15. Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876
16. Berardi D, Amore M, Keck PE Jr: Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998; 44:748-754
17. Paparrigopoulos T, Tzavellas E, Ferentinos P, et al: Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10:70-73
18. Looper KJ: Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics 2007; 48:1-9
19. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352:1112-1123
20. Gillman, P: Understanding toxidromes: serotonin toxicity: a commentary on Montanes-Rada et al. J Clin Psychopharmacol 2005; 25:625-626
21. Stöber G, Saar K, Rüschendorf F, et al: Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet 2000; 67:1201-1207
22. Stöber G, Kohlmann B, Siekiera M, et al: Systematic mutation analysis of KIAA0767 and KIAA1646 in chromosome 22q-linked periodic catatonia. BMC Psychiatry 2005; 5:36
23. Pfuhlmann B, Stöber G: The different conceptions of catatonia: historical overview and critical discussion. Eur Arch Psychiatry Clin Neurosci 2001; 251:4-7
24. Beld JT, Philbrick K, Rummans T: Periodic catatonia, in Catatonia: From Psychopathology to Neurobiology. Edited by Caroff SN, Mann SC, Francis A, et al. Washington, DC, American Psychiatric Publishing, 2004, pp 93-102
25. Stöber G, Seelow W, Ruschendorf F: Periodic catatonia: confirmation to linkange to chromosome 15 and further evidence for genetic heterogeneity. Hum Genet 2002; 111:323-330
26. Fink M, Taylor MA: The many faces of catatonia, in Catatonia: A Clinician's Guide to Diagnosis and Treatment. New York, Cambridge University Press, 2003, pp 59-60
27. Lee JW: Cycloid psychosis, catatonia, and periodic catatonia. Aust N Z J Psychiatry 38:975-976
28. Arora M, Praharaj SK: Butterfly glioma of corpus callosum presenting as catatonia. World J Biol Psychiatry 2007; 8:54-55
29. Carroll BT, Goforth HW: Medical catatonia, in Catatonia: From Psychopathology to Neurobiology. Edited by Caroff SN, Mann SC, Francis A, et al. Washington, DC, American Psychiatric Publishing, 2004, pp 123-125
30. Northoff G, Steinke R, Czcervenka C, et al: Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J Neurol Neurosurg Psychiatry 1999; 67:445-450
31. Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50:873-880
32. Carroll BT, Goforth HW, Thomas C, et al: Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neuroscience 2007; 19: 406-412
33. Carroll BT, Thomas C, Jayanti K, et al: Treating persistent catatonia when benzodiazepines fail. Curr Psychiatry 2005; 4:56-64
34. Mann SC, Caroff SN, Fricchione GL, et al: Malignant catatonia, in Catatonia: From Psychopathology to Neurobiology. Edited by Caroff SN, Mann SC, Francis A, Fricchione GL. Washington, DC, American Psychiatric Publishing, 2004, pp 111-115
35. Louis ED, Pflaster NL: Catatonia mimicking nonconvulsive status epilepticus. Epilepsia 1995; 36:943-945
36. Sengoku A, Takagi S: Electroencephalographic findings in functional psychoses: state or trait indicators? Psychiatry Clin Neurosci 1998; 52:375-381
37. Freudenrich O, McEvoy JP, Goff DC, et al: Catatonic coma with profound bradycardia. Psychosomatics 2007; 48:74-78
38. Carroll BT, Kennedy JC, Goforth HW: Approach to the differential diagnosis of catatonia. Medscape Psychiatry & Mental Health eJournal 1996; 1
39. Alisky JM: Lorazepam-reversible catatonia in the elderly can mimic dementia, coma, and stroke. Age Ageing 2007; 36:229
40. Carroll BT, Kennedy JC, Goforth HW: Catatonic signs in medical and psychiatric catatonias. CNS Spect 2000; 5:66-69
41. Fricchione GL, Huffman JC, Stern TA, et al: Catatonia, neuroleptic malignant syndrome, and serotonin syndrome, in The Massachusetts General Hospital Handbook of General Hospital Psychiatry. Edited by Stern TA, Fricchione GL, Cassem NH, et al. Philadelphia, Elsevier, 2004, p 516
42. Barnes MP, Sanders M, Walls JJ, et al: The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 1986; 49: 991-996
43. Suzuki K, Miura N, Awata S, et al: Epileptic seizures super-imposed on catatonic stupor. Epilepsia 2006; 47:793-798
44. Niraj A, Lloyd AJ: On catatonia, seizures, and bradycardia. Psychosomatics 2008; 49:86
45. Ahuja N, Carroll BT: Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:968-969
46. Ahuja N, Carroll BT, Lloyd AJ: Catatonia associated with systemic lupus erythematosus. Psychiatry Clin Neurosci 2007; 60:450-451
47. Ferrando SJ, Nims C: HIV-associated mania treated with electroconvulsive therapy and highly-active antiretroviral therapy. Psychosomatics 2006; 47:170-173
48. Waller K, Borik A, Choi C: Breast cancer, bipolar disorder, catatonia, and life-preserving electroconvulsive therapy. Psychosomatics 2000; 41:442-445
49. Catalano G, Catalano M, Rosenberg EI, et al: Another neuropsychiatric presentation of vitamin B12 deficiency? Psychosomatics 1998; 39:456-460
50. Caroff SN, Mann SC, Campbell EC: Neuroleptic malignant syndrome. Adverse Drug React Bull 2001; 209:799-802
51. Carroll BT, Goforth HW: Serum iron in catatonia. Biol Psychiatry 1995; 38:776-777
52. Lee JW: Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499-507
53. Peralta V, Cuesta MJ, Mata I, et al: Serum iron in catatonic and noncatatonic psychotic patients. Biol Psychiatry 1999; 45:788-790
54. Carroll BT: Catatonic stupor: diagnosis and treatment. Federal Practioner 2001; 18:48-54
55. Lachner C, Sandson NB: Medical complications of catatonia: a case of catatonia-induced deep venous thrombosis. Psychosomatics 2003; 44:512-514
56. McCall WV, Mann SC, Shelp FE, et al: Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. J Clin Psychiatry 1995; 56:21-25
57. Swartz C, Galang RL: Adverse outcome with delay in identification of catatonia in elderly patients. Am J Geriatr Psychiatry 2001; 9:78-80
58. Carroll BT: Catatonia on the consultation-liaison service. Psychosomatics 1992; 33:310-315
59. Hawkins JM, Archer KJ, Strakowski SM, et al: Somatic treatment of catatonia. Int J Psychiatry Med 1995; 25:345-369
60. Huang TL: Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia. Psychiatry Clin Neurosci 2005; 59:52-55
61. Schmider J, Standhart H, Deuschle M, et al: A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437-741
62. Kumar R: Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam. Aust N Z J Psychiatry 2001; 35:391
63. Lee JW, Schwartz DL, Hallmayer J: Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Ann Clin Psychiatry 2000; 12:89-96
64. Benazzi F: Parenteral clonazepam for catatonia. Can J Psychiatry 1991; 36:312
65. Ungvari GS, Leung CM, Wong MK, et al: Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994; 89:285-288
66. Ungvari GS, Chiu HFK, Chow LY, et al: Lorazepam for chronic catatonia: a randomized double-blind, placebo controlled cross-over study. Psychopharmacology 1999; 142:393-398
67. Clothier JL, Pazzaglia P, Freeman TW: Evaluation and treatment of catatonia. Am J Psychiatry 1989; 146:553-554
68. McEvoy JP: Relief from catatonic immobility can be maintained. J Clin Psychopharm 1986; 6:126-127
69. Manjunatha N, Saddichha S, Khess CR: Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review. Aust N Z J Psychiatry 2007; 41:625-627
70. Thomas P, Rascle C, Mastain B, et al: Test for catatonia with zolpidem. Lancet 1997; 349:702
71. Thomas P, Cottencin O, Rascle C, et al: J catatonia in French psychiatry: implications of the zolpidem challenge test. Psychiatr Annals 2007; 37:45-54
72. Caroff SN, Ungvari GS, Bhati MT, et al: Catatonia and prediction of response to electroconvulsive therapy. Psychiatr Ann 2007; 37:57-64
73. Suzuki K, Shindo T, Katsura M, et al: Resolution of catatonia by successful seizure induction via electroconvulsive therapy with electrodes applied bilaterally to the parietotemporal region. J ECT 2007; 23:103-105
74. Malur C, Francis A: Emergence of catatonia during ECT. J ECT 2001; 17:201-204
75. Petrides G, Divadeenam KM, Bush G, et al: Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry 1997; 42:375-381
76. Hudcova J, Schumann R: Electroconvulsive therapy complicated by life-threatening hyperkalemia in a catatonic patient. Gen Hosp Psychiatry 2005; 28:440-442
77. Magid M, Lapid MI, Sampson SM, et al: Use of electroconvulsive therapy in a patient 10 days after myocardial infarction. J ECT 2005; 21:182-185
78. Vittorio DM, Bolino F: A novel treatment option of bipolar depression with psychotic and catatonic features. Gen Hosp Psychiatry 2006; 28:364-365
79. Grisaru N, Chudakov B, Yaroslavsky Y, et al: Catatonia treated with transcranial magnetic stimulation. Am J Psychiatry 1998; 155:1626
80. Saba G, Rocamora JF, Kalalou K, et al: Catatonia and transcranial magnetic stimulation. Am J Psychiatry 2002; 159:1794
81. Carpenter S, Hatchett AD, Fuller MA: Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40:344-346
82. Munoz C, Yulan N, Achaval V, et al: Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008; 20:119-120
83. Northoff G, Eckert J, Fritze J: Glutamatergic dysfunction in catatonia? Successful treatment of three akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry 1997; 62:404-406
84. Gorforth H: Amantadine in catatonia due to major depressive disorder in a medically ill patient. J Neuropsychiatry Clin Neurosci 2007; 19:480
85. Carroll BT, Goforth HW, Thomas C, et al: Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19:406-412
86. Carpenter SS, Hatchett AD, Fuller MA: Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40: 344-346
87. McDaniel WW, Spiegel DR, Sahota AK: Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 2006; 18:234-237
88. Yoshida I, Monji A, Hashioka S, et al: Prophylactic effect of valproate in the treatment for siblings with catatonia: a case report. J Clin Psychopharmacology 2005; 5:504
89. Cassidy EM, O'Brien M, Osman MF, et al: Lethal catatonia responding to high-dose olanzapine therapy. J Psychopharmacology 2001; 15:302-304
90. Markham-Abedi C, McNeely C, DeLeon J: A case report with ziprasidone-induced catatonic symptoms. J Neuropsychiatry Clin Neurosci 2007; 19:476
91. Carroll BT, Lee JW: Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004; 65:1722-1723
92. Fink M, Taylor MA. Management of catatonia today, in Catatonia: A Clinicians Guide to Diagnosis and Treatment. New York, Cambridge University Press, 2003, p 150
93. Naber D, Holzbach R, Perro C, et al: Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 1992; 160:54-59
94. Hung YY, Yang PS, Huang TL: Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry Clin Neurosci 2006; 60:256-258
95. Numata S, Kato O, Misawa H, et al: Treatment of catatonia with olanzapine. German Journal of Psychiatry 2002; 5:115-116
96. Valevski A, Loebl T, Karen T, et al: Response of catatonia to risperidone: two case reports. Clin Neuropharmacology 2001; 24:228-231
97. Bahro M, Kampf C, Strnad J: Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr Scand 1999; 99:223-224
98. Markham-Abedi C, McNeely C, DeLeon J: A case report with ziprasidone-induced catatonic symptoms. J Neuropsychiatry Clin Neurosci 2007; 19:476-477
99. Van Den Eede F, Van Hecke J, Van Dalfsen A, et al: The use of atypical antipsychotics in the treatment of catatonia. European Psychiatry 2005; 20:422-429